[go: up one dir, main page]

NO996161D0 - A controlled release formulation for heavily soluble basic drugs - Google Patents

A controlled release formulation for heavily soluble basic drugs

Info

Publication number
NO996161D0
NO996161D0 NO996161A NO996161A NO996161D0 NO 996161 D0 NO996161 D0 NO 996161D0 NO 996161 A NO996161 A NO 996161A NO 996161 A NO996161 A NO 996161A NO 996161 D0 NO996161 D0 NO 996161D0
Authority
NO
Norway
Prior art keywords
controlled release
release formulation
soluble basic
basic drugs
heavily soluble
Prior art date
Application number
NO996161A
Other languages
Norwegian (no)
Other versions
NO996161L (en
NO310095B1 (en
Inventor
Neville W Broad
Alan F Carmody
Liam C Feely
Brian C Withers
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to NO996161A priority Critical patent/NO310095B1/en
Publication of NO996161D0 publication Critical patent/NO996161D0/en
Publication of NO996161L publication Critical patent/NO996161L/en
Publication of NO310095B1 publication Critical patent/NO310095B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO996161A 1997-06-11 1999-12-13 A controlled release formulation for heavily soluble basic drugs NO310095B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO996161A NO310095B1 (en) 1997-06-11 1999-12-13 A controlled release formulation for heavily soluble basic drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1997/010705 WO1998056357A1 (en) 1995-12-19 1997-06-11 A controlled release formulation for poorly soluble basic drugs
NO996161A NO310095B1 (en) 1997-06-11 1999-12-13 A controlled release formulation for heavily soluble basic drugs

Publications (3)

Publication Number Publication Date
NO996161D0 true NO996161D0 (en) 1999-12-13
NO996161L NO996161L (en) 1999-12-13
NO310095B1 NO310095B1 (en) 2001-05-21

Family

ID=22261117

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996161A NO310095B1 (en) 1997-06-11 1999-12-13 A controlled release formulation for heavily soluble basic drugs

Country Status (4)

Country Link
NO (1) NO310095B1 (en)
SI (1) SI20108B (en)
SK (1) SK282427B6 (en)
WO (1) WO1998056357A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3668000A (en) * 1999-04-29 2000-11-17 Russinsky Limited Compounds
EP1118333A1 (en) * 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions with enhanced oral bioavailability
UA76967C2 (en) * 2000-11-27 2006-10-16 Сандоз Аг Azithromycin in the form of a monohydrate, a pharmaceutical composition and a method for the preparation thereof
EP1492504A2 (en) * 2002-04-03 2005-01-05 Ranbaxy Laboratories, Ltd. Taste masked compositions of erythromycin a and derivatives thereof
SI21300A (en) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical compositions with alginates
CN100336511C (en) * 2002-11-15 2007-09-12 江苏豪森药业股份有限公司 Release-controlled oral Roxithromycin formulation
WO2004112711A2 (en) * 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
WO2005053656A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60163823A (en) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd Orally administered formulation
DE3583799D1 (en) * 1985-01-11 1991-09-19 Abbott Lab Ltd SOLID PREPARATION WITH SLOW RELEASE.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs

Also Published As

Publication number Publication date
SK282427B6 (en) 2002-01-07
WO1998056357A1 (en) 1998-12-17
SI20108B (en) 2001-12-31
SI20108A (en) 2000-06-30
NO996161L (en) 1999-12-13
NO310095B1 (en) 2001-05-21
SK161299A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
HUP9800516A3 (en) A controlled release formulation for poorly soluble basic drugs
NO996161D0 (en) A controlled release formulation for heavily soluble basic drugs
MA26576A1 (en) EXTENDED RELEASE ORAL PHARMACEUTICAL FORMULATION
MA26577A1 (en) PULSED RELEASE ORAL PHARMACEUTICAL FORMULATION
NO20000735L (en) Sustained release drug delivery device
ATE234078T1 (en) PHARMACEUTICAL OMEPRAZOLE FORMULATION
EE200000098A (en) A pharmaceutical composition for combining piperidinoalkanol decongestant
EP1124543A4 (en) Controlled release formulation for water soluble drugs
EP0807433A4 (en) PREPARATION FOR PROLONGED RELEASE
EE200000361A (en) Device for administering a drug-containing fluid
DE69904312D1 (en) PHARMACEUTICAL AEROSOL FORMULATION
DE69833464D1 (en) A pharmaceutical composition containing 2,3-diaryl-pyrazolo1,5-bPyridazine derivatives
IT1294748B1 (en) FORMULATION FOR A TRANSDERMAL DEVICE
BR9607752B1 (en) controlled release microcapsule pharmaceutical formulation.
ZA982872B (en) Pharmaceutical formulation
PT1015444E (en) PYRIMIDINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION
IL135457A0 (en) Extended release formulation
NO20001375D0 (en) Drug formulation with controlled release
PT868911E (en) RAPAMICINE FORMULATIONS FOR ORAL ADMINISTRATION
ID30032A (en) PHARMACEUTICAL FORMULATION
NO996044L (en) Rapamycin formulations for oral administration
GB9709739D0 (en) Pharmaceutical formulation
NO980072D0 (en) Soluble release mechanism for moving joints
HRP970325B1 (en) Controlled release formulation for poorly soluble basic drugs
GB9724175D0 (en) A pharmaceutical formulation

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BGP PRODUCTS OPERATIONS GMBH, CH

MK1K Patent expired